Abstract
Extracts of Hypericum perforatum (St. John’s wort) have gained popularity as an alternative to synthetic antidepressants or behavioural therapy in the treatment of mild to moderate forms of depressive disorders. The present article reviews and discusses the available preclinical data that are in favour of or against the use of Hypericum perforatum as an antidepressant. Multiple chemical entities constitute extracts from Hypericum perforatum. The effects of Hypericum perforatum extracts have been compared with those of conventional antidepressants in different in vitro and in vivo biochemical studies of antidepressant-like activity and in behavioural pharmacology studies using animal models of depression. Recent investigations have indicated that Hypericum perforatum, like conventional antidepressants, is involved in the regulation of genes that control hypothalamic-pituitary-adrenal axis function and influence, at least in part, stress-induced effects on neuroplasticity and neurogenesis. From the available evidence it can be concluded that data supporting the use of Hypericum perforatum for the treatment of depression are present in literature. However, results from experiments carried out with extracts or pure compounds do not always resemble biochemical and pharmacological profile characteristic of synthetic antidepressants. In particular, the majority of findings in preclinical studies have been obtained with high doses of pure compounds and extracts that are not comparable to the concentrations of single active constituents after oral administration in humans.
Keywords: Hypericum perforatum, St. John’s wort, depression, antidepressant activity, rats, mice.
CNS & Neurological Disorders - Drug Targets
Title:Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression
Volume: 12 Issue: 4
Author(s): Rosalia Crupi, Yousef Abdel Kareem Abusamra, Edoardo Spina and Gioacchino Calapai
Affiliation:
Keywords: Hypericum perforatum, St. John’s wort, depression, antidepressant activity, rats, mice.
Abstract: Extracts of Hypericum perforatum (St. John’s wort) have gained popularity as an alternative to synthetic antidepressants or behavioural therapy in the treatment of mild to moderate forms of depressive disorders. The present article reviews and discusses the available preclinical data that are in favour of or against the use of Hypericum perforatum as an antidepressant. Multiple chemical entities constitute extracts from Hypericum perforatum. The effects of Hypericum perforatum extracts have been compared with those of conventional antidepressants in different in vitro and in vivo biochemical studies of antidepressant-like activity and in behavioural pharmacology studies using animal models of depression. Recent investigations have indicated that Hypericum perforatum, like conventional antidepressants, is involved in the regulation of genes that control hypothalamic-pituitary-adrenal axis function and influence, at least in part, stress-induced effects on neuroplasticity and neurogenesis. From the available evidence it can be concluded that data supporting the use of Hypericum perforatum for the treatment of depression are present in literature. However, results from experiments carried out with extracts or pure compounds do not always resemble biochemical and pharmacological profile characteristic of synthetic antidepressants. In particular, the majority of findings in preclinical studies have been obtained with high doses of pure compounds and extracts that are not comparable to the concentrations of single active constituents after oral administration in humans.
Export Options
About this article
Cite this article as:
Crupi Rosalia, Abusamra Abdel Kareem Yousef, Spina Edoardo and Calapai Gioacchino, Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/1871527311312040006
DOI https://dx.doi.org/10.2174/1871527311312040006 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine Meet Our Associate Editor
MicroRNA The Many Faces of Amyloid β in Alzheimers Disease
Current Molecular Medicine Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Eremurus spectabilis, Rich Source of Isoorientin: Isolation, Quantification and Anti-Cancer Activity on SH-SY5Y Neuroblastoma Cells
Current Pharmaceutical Analysis Treatment of Insulin Resistance in the Neurodegeneration
Recent Patents on CNS Drug Discovery (Discontinued)